Core Insights - The establishment of the Ningbo Tonggao Gongrong Private Equity Investment Fund marks a significant development in the financial landscape of Ningbo, with a registered scale of 2 billion yuan, making it the largest single AIC equity investment fund in the city [1] - The fund aims to focus on eight key industrial sectors, including digital industry, artificial intelligence, new energy vehicles, high-end equipment manufacturing, biomedicine, new materials, fine chemicals, and modern productive services [1][2] - The Industrial and Commercial Bank of China (ICBC) has cumulatively registered AIC equity investment funds totaling 5 billion yuan in Ningbo, positioning itself as the leading commercial bank in the city [1] Investment Strategy - The Ningbo Tonggao Gongrong Private Equity Investment Fund is a collaborative effort involving ICBC Financial Asset Investment Co., Ningbo Tongshang Holding Group Co., and Ningbo High-tech Venture Capital Co., focusing on precision investment and nurturing to attract quality resources for regional industrial upgrades [1][2] - Following the expansion of the financial asset investment company's equity investment pilot program, ICBC Ningbo Branch has successfully launched its first equity investment project under the Ningbo Gongrong New Momentum Fund, indicating a proactive approach to leveraging policy opportunities [2] - The bank plans to continue utilizing its comprehensive advantages to support key industries in Ningbo, emphasizing the importance of "long-term capital," "patient capital," and "strategic capital" in fostering technological innovation [2]

Policy Developments - The National Medical Products Administration (NMPA) emphasizes the need for comprehensive drug regulation reform to enhance drug safety and support high-quality development in the pharmaceutical industry [2] Drug and Device Approvals - Zai Lab's new drug application for JAK inhibitor, Tofacitinib, for treating severe alopecia areata has been accepted by the NMPA, marking its second indication for this drug [4] - Tonghua Dongbao's insulin injection has received marketing approval in Nicaragua, expanding its overseas sales potential [5] - BeiGene's new indication application for its BCL2 inhibitor, Sotorasib, for treating mantle cell lymphoma has been accepted by the NMPA [6] - Yilian Biopharma's antibody-drug conjugate targeting VEGF has received clinical trial approval in the U.S. [7] - Zhengda Tianqing's combination therapy for advanced hepatocellular carcinoma has shown positive results in a Phase III trial, with plans for a market application in November 2024 [8] - Rongchang Biopharma's clinical trial application for its ADC molecule RC278 has been accepted by the NMPA [9][10] Capital Markets - Easternova Biotechnology has submitted its IPO application to the Hong Kong Stock Exchange, focusing on regenerative medical materials [12] - China National Pharmaceutical Group plans to acquire 100% of Jinsui Technology for 302 million yuan, enhancing its e-commerce operations in health products [13] Industry Developments - Suzhou Industrial Park has launched a plan to accelerate the development of the biopharmaceutical and health industry, focusing on innovation and enterprise growth [15] - Ganli Pharmaceutical has signed a cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese pharmaceutical company to enter Brazil's PDP program [16]

日前，高校科技成果转化基金子基金管理机构遴选公告公布，首期面向全国公开遴选人工智能领域 子基金的基金管理机构。 据悉，四川高校科技成果转化创业投资基金（简称"高校科技成果转化基金"） 是一只在中国证券 投资基金业协会备案的创业投资基金，旨在国家法律允许范围内开展投资活动，保护全体合伙人合 伙权益，为全体合伙人获得最优投资回报。高校科技成果转化基金将借助高校和科研院所的科技成 果资源优势，促进全国高校及科研院所的科技成果转化应用，赋能战略新兴产业、未来产业的发 展，培育新质生产力。 高校科技成果转化基金整体规模100亿元，首期规模30亿元。重点投向人工智能、新能源、先进材 料、电子信息、高端装备制造、生物医药、未来交通七大领域。 来源：高校科技成果转化基金官网 对接需求请扫码 每日｜荐读 热文： 社会LP去哪了 热文： 购基金井喷，巨头们开始"买买买" 报告： 独角兽的"新双轮驱动"：《2025中国CVC影响力报告》发布 报告： 哪些LP在活跃出资？——《LP全景报告2024》发布 ...

昨天（5月12日），《苏州工业园区加快生物医药及大健康产业腾飞行动计划（2025-2027）》正式 发布。聚焦创新药、高端医疗器械、大健康等重点领域，《行动计划》重点围绕企业规模化发展、优质 增量项目落地、创新产品上市、创新产品应用推广、股权融资、信贷支持、人工智能赋能、体制机制创 新等八个方面，将通过择优精准扶持、构建"5511"企业培育体系，助力园区生物医药及大健康产业腾飞 发展。 以制度创新破解生物医药产业发展瓶颈，园区将按照《行动计划》，发挥中新合作和自贸区优势， 深入开展生物医药全产业链开放创新；纳入国家创新药临床试验审评审批试点和药品补充申请审评审批 试点，缩短审评审批时限；支持全球领先的食品、保健品在保证产品质量且符合法律法规及相应食品生 产许可审查细则等规定的情况下在苏州工业园综合保税区内从事分包装业务，分包装后的产品通过跨境 电商模式进入国内市场。 在支持企业规模化发展方面，园区将聚焦培优育强，重点支持企业加大固定资产投入、扩大企业规 模、做大营业收入、增大研发投入和上下游企业收并购；在加快优质增量项目落地投产方面，将聚焦招 大引强，重点支持世界500强、中国500强、中国医药工业百强企业， ...

5月8日，上海科创银行联合浦发银行、上海国投先导私募基金在上海举办"临界点・跃迁力——硬科技 及医疗项目融资路演专场"。会议旨在聚焦前沿领域优质项目，促进头部资本与科技创新精准对接，助 力优质项目全生命周期加速成长。 来自人工智能、集成电路、生物医药领域的多家高成长科创企业登台路演介绍自身技术优势、产业化进 展以及融资需求。30余家知名风险投资机构参与本次路演，会后与意向企业进一步资本对接、深度交 流。 浦发银行总行战略客户部总经理李林女士、上海国投先导私募基金管理有限公司副总经理何苗女士、上 海科创银行有限公司行长陆珏女士出席活动并致辞。 浦发银行总行战略客户部总经理李林 上海科创银行行长陆珏在致辞中表示，上海科创银行始终致力于成为科创生态圈的超级链接者，今天， 我们很高兴与浦发银行、上海国投先导基金的专业团队强强联手，汇聚了经验丰富的耐心资本和产业资 源，为优秀科创项目提供强有力的生态能量。我们相信，在生态伙伴的共同努力下，大家一定能并肩跨 越临界点、共同拥抱新时代下的新机遇。 本次路演成功搭建了科创企业与投资机构之间沟通的桥梁，促进了科技与资本的深度融合。上海科创银 行将持续秉持服务科创企业的初心、不断 ...

Group 1: Event Overview - The "AI Empowering the Biopharmaceutical Industry Salon" was successfully held on May 8, 2025, in Shanghai, focusing on the innovative applications of AI technology in drug development and manufacturing [1] - The event gathered industry leaders, technical experts, and representatives from well-known companies for in-depth discussions and site visits [1] Group 2: Strategic Missions and Directions - The Shanghai Biopharmaceutical Industry Association outlined three strategic missions: building a collaborative innovation platform, fostering cross-industry ecosystems, and creating a global innovation hub [2] - Three key focus areas for industry development were proposed: technological innovation, application implementation, and regulatory support [2] Group 3: Industry Ecosystem and Investment - The Lingang Life Bay has established itself as a global biopharmaceutical innovation hub, attracting over 200 companies and forming three major industry clusters: biopharmaceuticals, high-end medical devices, and CRO/CDMO [3] - The Lingang Life Bay Fund promotes the deep integration of AI and healthcare through a unique "capital + service + platform" model [3] Group 4: AI Applications and Case Studies - Various experts shared insights on AI's role in pharmaceutical manufacturing, including digital transformation and energy-efficient solutions [5][6] - A roundtable discussion addressed challenges and opportunities in integrating AI throughout the drug development process, from laboratories to production [6] Group 5: Company Spotlight - Junshi Biosciences, established in 2012, is a global biopharmaceutical company with a total production capacity of 46,500 liters, expandable to 120,000 liters [7] - The company aims to provide accessible treatment options globally and has implemented AI-driven systems that improved production efficiency by 20% [7] Group 6: Future Outlook - The salon emphasized the importance of AI in the biopharmaceutical sector and the need for continuous industry collaboration to enhance China's competitive position in global markets [8]

值得一提的是，在市委统战部的指导下，由一财万项策划和执行的首届"上海青年科创嘉年华"也取得了良 好反响。嘉年华直面青年创新创业"三有三缺"特点，即"有青春、有创意、有勇气"，但"缺资金、缺经验、 缺资源"，邀请近百家投资机构、吸引近百个创业项目共同参与，旨在以"核心赛道强聚焦、新兴领域广覆 盖、产业生态全呈现"的布局，创设"伯乐"与"千里马"的大集会，启发前沿创新思想的大碰撞，促成多维创 大放送两大板块全程高能。《活力城市》板块感受上海的创新温度和创业浓度；《新质青年》板块聚焦新 科技，对话新未来。结合论坛现场与Y50大放送的嘉宾精彩发言，第一财经报道团队通过视频与文字新闻 形式及时传递优质内容，其中由视频新闻衍生的"上海瞪羚企业数量全球第一"、"上海科创中心建设十年磨 一剑"等话题均登上社交媒体热榜，《宇树王兴兴：第一桶金来自上海，坚持做人形机器人有几个原 因》、《上海国投公司总裁：已搭建"六大母基金"为主干的矩阵》等深度图文报道亦受到全网广泛关注。 5月10日，第六届上海创新创业青年50人论坛在上海中心开幕。本届论坛以"青年与城市共成长"为主 题，聚焦青年创新创业全过程、全要素、全链条，设置了主旨演讲、年 ...

Core Insights - The establishment of the Nanjing Biomedical Sub-center has facilitated the transfer and commercialization of research outcomes from 68 universities, resulting in 1,123 selected pharmaceutical achievements and 31 projects being established [1][2] - The sub-center has created a financial support system with a scale of 8.4 billion yuan, including various funding sources to assist startups and projects [2] Group 1 - The Nanjing Biomedical Sub-center has engaged with 68 universities and selected 1,123 pharmaceutical achievements, leading to the establishment of 31 projects [1] - The sub-center provides significant support to startups, including access to expensive laboratory equipment, which alleviates financial burdens for new companies [1] - The rapid establishment of companies, such as Innos (Nanjing) Biotechnology Co., demonstrates the effectiveness of the sub-center in facilitating research commercialization [1] Group 2 - A comprehensive financial support system of 8.4 billion yuan has been established, encompassing government funding, angel funds, and bank loans [2] - The sub-center has developed a team of over 140 technical managers to provide one-stop support for university teams, aiding in the swift establishment and growth of projects [2] - Future plans for the sub-center include enhancing collaboration with universities and enterprises to promote high-quality development in the biomedical industry [2]

Core Viewpoint - The article emphasizes the establishment of four industry advancement offices focusing on artificial intelligence, robotics, biomedicine, and next-generation information communication to drive key industries forward and achieve economic development goals [1][2]. Group 1: Industry Development Strategy - The establishment of the four industry advancement offices is a strategic move by the municipal government to integrate resources and innovate mechanisms for industry development [1]. - The focus will be on four key areas: enhancing industry planning, ensuring project implementation, building an industrial ecosystem, and strengthening overall coordination [1]. Group 2: Implementation and Support - There is a call for innovative thinking and effective coordination among various departments to support the industry advancement offices in their functions [2]. - The emphasis is placed on cultivating and identifying talent through practical results in industry development, ensuring that responsibilities are effectively managed [2].

Core Insights - Shanghai Guotou Company has invested in over 2,800 enterprises, including more than 100 listed companies, with over 90% of investments focused on integrated circuits, biomedicine, and artificial intelligence [1][4]. Group 1: Investment Strategy - The company has established a fund matrix consisting of six main funds, including the mother fund for three leading industries, future industry fund, state-owned mother fund, and entrepreneurial guidance fund [4]. - The main funds have a duration of 12-15 years to align with the long development cycles of hard technology [4]. - Sub-funds focus on early-stage startups and specific sectors, while the future industry fund emphasizes cutting-edge, cross-disciplinary, and disruptive innovations [4][5]. Group 2: Sector Focus - In the integrated circuit sector, the company focuses on process manufacturing, chip design, and core supporting upgrades to ensure a self-controlled industrial chain [5]. - In biomedicine, the focus is on innovative drugs, devices, and upstream supply chains, with the establishment of acquisition funds to integrate resources for leading enterprises [5]. - In artificial intelligence, the emphasis is on AI chips, general and vertical models, high-quality data, embodied intelligence, edge AI, and autonomous driving [5]. Group 3: Talent and Innovation Support - The company is enhancing collaborative networks to capture "innovation signals" and improve talent-driven transformation mechanisms [5][6]. - Partnerships with key universities, research institutions, and high-quality incubators are being developed to facilitate the transition from laboratory research to practical applications [5]. - A professional platform for innovation empowerment has been established, providing a comprehensive service system to address challenges faced by young talents in entrepreneurship [6].